Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$585.74 USD

585.74
568,363

+2.74 (0.47%)

Updated Jul 23, 2024 04:00 PM ET

Pre-Market: $584.97 -0.77 (-0.13%) 8:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans

by Zacks Equity Research

NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

by Zacks Equity Research

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Indrajit Bandyopadhyay headshot

4 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

by Zacks Equity Research

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

by Zacks Equity Research

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

by Zacks Equity Research

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

by Zacks Equity Research

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

by Zacks Equity Research

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump

by Zacks Equity Research

Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.

Mark Vickery headshot

Manufacturing Data Improves, Bond Yields Stay Elevated

by Mark Vickery

We got some slightly better September Manufacturing numbers than expected from the final S&P PMI and ISM reports.

Why McKesson (MCK) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

by Zacks Equity Research

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Sumit Singh headshot

4 Stocks That Stand Out on Attractive Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, SFM, MOH and MCK are sound enough to meet financial obligations.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab's (ECL) strength in its business raises optimism about the stock.